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ABSTRACT 
Background: The most common serious adverse f- 
fects (AEs) associated with NSAID therapy are bleed- 
ing and perforated gastroduodenal ulcers. These AEs are 
dose related, and reduced oral clearance of NSAIDs as- 
sociated with polymorphisms of cytochrome P450 (CYP) 
would, theoretically, increase the risk for AEs. 
Objectiv= The purpose of this study was to deter- 
mine whether polymorphisms of the CYP2C9 geno- 
type are associated with the development of serious 
complications ofNSAID-related ulcers. 
Methods: We examined the records of patients with 
complications of serious NSAID-related ulcers who 
were hospitalized from November 2001 to December 
2003. Diagnosis was confirmed by endoscopy or ab- 
dominal surgery, and a group of consecutive subjects 
was identified for genetic analysis. CYP2C9 allele fre- 
quencies were determined and compared with those in 
a matched cohort of subjects receiving stable weekly 
maintenance doses of oral coumarin anticoagulants. 
Allele frequencies also were compared with those in 
matched cohorts from earlier studies. 
Results: All 26 subjects with serious NSAID-related 
ulcers were white, 15 (58%) were female, and the 
median age was 74.5 years (range, 32-96 years). All 
87 subjects in the reference group were white, 24 
(28%) were female, and the median age was 69 years 
(range, 48-81 years). CYP2C9 genotype frequencies 
did not differ significandy between subjects with 
serious complications of NSAID-related ulcers and 
subjects using oral coumarin anticoagulants. The 
genotype frequencies in both groups were similar to 
those reported in previous tudies in white subjects. 
Conclusion: The CYP2C9 genotype was not a sig- 
nificant or clinically relevant risk factor in the de- 
velopment of serious NSAID-related ulcers in this 
group of subjects. (Clin Ther. 2006;28:1670-1676) 
Copyright © 2006 Excerpta Medica, Inc. 
Key words: NSAID, ulcer, cytochrome P450, 
polymorphism. 
INTRODUCTION 
NSAIDs are among the most frequently prescribed 
medications in the world, with ~30 million people 
using them on a daily basisA Bleeding and perforated 
gastroduodenal ulcers are among the most serious 
complications of NSAID therapy and may lead to 
significant morbidity, mortality, and financial costs. 
Among chronic NSAID users, the annual incidence 
of serious NSAID-related ulcers requiring treatment 
and hospitalization is estimated at1% to 2%, with an 
associated mortality rate of 10% to 15%. 2-4 In The 
Netherlands, the annual direct medical costs of the 
complications of serious NSAID-related ulcers have 
been estimated to be more than E42 million. 4
Several additional risk factors for NSAID-related 
ulcers have been identified, including advanced age, 
history of ulceration, and Helicobacter pylori nfec- 
tion. s,6 The risk of NSAID-related ulcers is influenced 
by the type of NSAID, dose, and use of >1 NSAID 
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simukaneously. 7-9Concomitant use of other drugs, 
such as steroids, anticoagulants, platelet inhibitors, 
and selective serotonin reuptake inhibitors, may fur- 
ther increase the risk for serious ulcers. 1°,11 Coexisting 
systemic disorders, such as diabetes mellitus and de- 
bilitating rheumatic diseases, also have been identified 
as risk factors. 12 In daily clinical practice, however, se- 
rious complications of NSAID-related ulcers also may 
be seen in subjects who lack obvious risk factors (ie, 
subjects aged <60 years who are otherwise healthy). It
is possible, therefore, that other unidentified risk fac- 
tors for NSAID-related ulcers exist. 
The cytochrome P450 (CYP) system is a large group 
of hemoproteins that catalyze the metabolism ofmany 
different chemicals. In humans, most drugs are acti- 
vated and detoxified by 4 CYP families (CYP1, CYP2, 
CYP3, and CYP4). 13 The CYP2C9 isozyme has been 
found to catalyze at least part of the metabolism of a 
number of drugs, including warfarin, tolbutamide, 
losartan, phenytoin, and at least 16 different NSAIDs, 
including acetylsalicylic acid, celecoxib, diclofenac, 
flurbiprofen, ibuprofen, indomethacin, meloxicam, 
and naproxen34 Apart from the wild-type protein, 
CYP2Cg*I, at least 5 CYP2C9 genetic polymorphisms 
with reduced metabolic activity have been observed, ls 16 
Two of these variants, CYP2C9"2 and CYP2C9"3, 
appear to have significant functional effects and have 
been found in relatively high frequencies in the white 
population, although they seem to be much less preva- 
lent in other racial groups. 17-19 In other studies, the 
CYP2C9"4 variant was found in Japanese subjects but 
not in white subjects; the CYP2C9"5 variant was found 
in black and Hispanic subjects but not in white sub- 
jects; and the CYP2Cg*6 variant was found in 1 black 
subject who experienced drug toxicity after receiving 
normal doses of phenytoin. 19-*'° 
The normal functioning wild-type of CYP2C9, 
CYP2Cg*I, has been reported to have a population 
frequency of 65% in white subjects, 87% in black 
subjects, and 96% in Asian subjects. 17,1s,21~2 The 
CYP2C9"2 allele has a single base substitution at 
position 144, which results in a change from argi- 
nine to cysteine. Subjects with the heterozygous 
CYP2C9"1/'2 genotype appear to exhibit a minor 
reduction i  catalytic activity of the CYP2Cg-encoded 
enzyme. Studies have reported high population fre- 
quencies of this genotype in white (20.4%) and 
black (8.7%) subjects but not in Asian subjects (0%). 
A moderate reduction in the functional activity of 
CYP2C9 has been noted in subjects with the homozy- 
gous CYP2C9"2/'2 genotype, but the population fre- 
quency of the CYP2C9"2/'2 genotype ismuch lower 
(0.9% in white subjects and 0% in black and Asian 
subjects). The CYP2C9"3 allele has a single base sub- 
stitution at position 359, which results in an amino 
acid change from isoleucine to leucine. The catalytic 
activity of the CYP2C9*3-encoded enzyme appears 
to be much lower than that of enzymes encoded by 
the wild-type, CYP2C9*I. Subjects with the heterozy- 
gous CYP2C9"1/'3 genotype and those with the com- 
pound heterozygous CYP2C9"2/'3 genotype appear 
to exhibit a moderate reduction in catalytic activity. 
The population frequency of the CYP2C9"1/'3 geno- 
type has been reported as 11.6% in white subjects, 
4.3% in black subjects, and 3.5% in Asian subjects, 
whereas the population frequency of the CYP2C9"2/'3 
genotype has been reported as 1.4% in white subjects 
and 0% in black and Asian subjects. 17,1s-*-l-9-z The 
homozygous CYP2C9"3 genotype is associated with a 
very low level of catalytic activity, and the frequency 
of the CYP2C9"3/'3 variant has been reported to be 
only 0.4% in white subjects and 0% in black and 
Asian subjects. 17,1s~-1,22 
CYP2C9 polymorphisms have been associated with 
changes in the pharmacokinetics of some frequently 
used NSAIDs. 17-19,23 Relative to subjects with the 
homozygous CYP2C9*I genotype, oral clearance of 
celecoxib was reduced by 77% in subjects with the 
homozygous CYP2C9"3 genotype and by 32% in 
subjects with the heterozygous CYP2C9"3 genotype. 
Oral clearance of ibuprofen was reduced by 45% in 
subjects with the homozygous CYP2C9"3 genotype 
and by 28% in subjects with the heterozygous 
CYP2C9"3 genotype. Oral clearance of diclofenac was 
reduced by 14% in subjects with the homozygous 
CYP2C9"3 genotype and by 5% in subjects with 
the heterozygous CYP2C9"3 genotype. Among homo- 
zygous and heterozygous CYP2C9"2 subjects, oral 
clearance of celecoxib and diclofenac was similar or 
even greater than the clearance in those with the wild- 
type, CYP2Cg*I. However, for ibuprofen, subjects 
with the homozygous CYP2C9"2 genotype had a 22% 
reduction i  oral clearance, and heterozygous subjects 
had a 12% reduction. 
Serious adverse vents associated with NSAID ther- 
apy, such as bleeding and perforated gastroduodenal 
ulcers, are dose related, which raises the question of 
whether the reduced NSAID clearance associated with 
i . . . . . . . . .  
CYP2C9 polymorphisms may increase the risk of se- 
rious NSAID-related gastroduodenal ulcers. If so, 
CYP2C9 allele frequencies would be expected to dif- 
fer from those in the general population. To test this 
hypothesis, we examined CYP2C9 allele frequencies 
in a group of white subjects from The Netherlands 
with serious NSAID-related ulcers and compared 
them with frequencies in a group of matched control 
subjects using oral coumarin anticoagulants and with 
those reported in white subjects in earlier studies, ly
SUBJECTS AND METHODS 
Subjects 
Serious NSAID-related ulcers were defined in this 
study as ulcerations of the stomach or proximal duo- 
denum causing pain, perforation, obstruction, or 
bleeding that occurred uring the time the subject was 
taking NSAIDs and resulted in treatment and hospi- 
talization. We identified all consecutive subjects with 
serious gastroduodenal tflcers who were hospitalized at 
the Medisch Spectrum Twente Hospital in Enschede, 
The Netherlands, from November 2001 through De- 
cember 2003. The diagnosis was confirmed by en- 
doscopy or abdominal surgery. If diagnostic procedures 
were not performed because of comorbidity or ad- 
vanced age, subjects with gastroduodenal ulcers were 
identified on the basis of a clinical presentation of
upper gastrointestinal bleeding with hematemesis or
melena. In a few subjects, the diagnosis was confirmed 
during autopsy. Subjects were eligible for inclusion if 
they reported using an NSAID at any time up to the 
diagnosis of a gastroduodenal ulcer. 
Subjects were excluded if written informed consent 
could not be obtained, if they reported not having used 
NSAIDs, if endoscopy or surgery did not reveal gastric 
or duodenal ulcers, if a malignancy ofthe stomach was 
found, or if another cause was determined for upper 
intestinal bleeding (eg, diffuse gastritis, esophagogas- 
tric varices, arteriovenous malformations, or Mallory- 
Weiss tears). 
CYP2C9 allele frequencies also were determined 
in a matched cohort of subjects using oral coumarin 
anticoagulants at stable weekly maintenance doses 
under supervision of the Thrombosis Services at the 
Medisch Spectrum Twente Outpatient Clinic in 
Oldenzaal, The Netherlands. 
The study was approved by the Medical Ethics 
Reviewing Committee ofthe Medisch Spectrum Twente 
Hospital, Enschede, The Netherlands. 
Methods 
CYP2C9 genotyping was performed using a stan- 
dard polymeric hain reaction technique with relevant 
test controls. This technique has been described in an 
earlier study of genetic polymorphism. 24 
CYP2C9 allele frequencies were compared using 
the Pearson X2 test, and, in cases in which the expect- 
ed values were low, the Fisher exact est was used. All 
analyses were performed using SPSS for Windows, 
version 12.0.1 (SPSS Inc., Chicago, Illinois). 
Based on previous tudies of allele variants, ly-19as 
we assumed that the presence of the variant allele 
CYP2C9~2 or CYP2C9~3 would increase a subject's 
risk for serious NSAID-related gastroduodenal ulcers. 
Based on previously published frequency data for this 
population, we expected ~35% (30/87) of the subjects 
in the reference group to have variant alleles. Assuming 
a ratio of ~3 for the comparison of reference subjects 
and subjects with serious NSAID-related ulcers, a power 
of 80%, 0~ = 0.05, and an odds ratio of 3, we calculat- 
ed that it would be necessary to examine CYP2C9 
allele frequencies in 35 subjects with serious NSAID- 
related gastroduodenal ulcers. 
RESULTS 
A cohort of 26 consecutive subjects with serious 
NSAID-related ulcers was selected for CYP2C9 
allele analysis. All subjects were white, 15 (58%) were 
female, and the median age was 74.5 years (range, 
32-96 years). Eleven (42%) of the subjects used 
diclofenac, 4 (15%) used ibuprofen, 4 (15%) used 
naproxen, 4 (15%) used rofecoxib, 2 (8%) used 
diclofenac/misoprostol, and 1 (4%) used meloxicam 
(Table I). Seven (27%) patients used more than the 
maximum recommended ose of NSAID, and 
5 (19%) used >1 NSAID concurrently. Concomitant 
use of low-dose aspirin was reported by 6 (23%) sub- 
jects, coumarin derivatives by 5 (19%), steroids by 
4 (15%), low-molecular-weight heparin by 2 (8%), 
and selective serotonin reuptake inhibitors by I (4%). 
Five (19%) subjects used either proton pump in- 
hibitors or high-dose histamine2-receptor antagonists. 
Only 1 subject had a history of gastroduodenal ulcers. 
Testing for H pylori was performed on biopsy speci- 
mens from the gastric mucosa of 20 subjects by histo- 
logic examination using hematoxylin and eosin 
staining and immunohistochemical H pylori anti- 
body staining. The results were positive in 5 (25%) 
subjects. 
Table I. Characteristics of white subjects with serious NSAID-related ulcers by sex, age, weight, NSAID type, dose ,  
expected effect ofCYP2C9 genotypes on NSAID pharrnacokinetics, and CYP2C9 genotype. 
Expected Effect 
Weight, of CYP2C9 CYP2C9 
Subject Sex Age, y kg NSAID Dose* Genotypef Variant 
1 M 79 75 Diclofenac/ Medium Minor *// '1 (wild-type) 
misoprostol 
2 F 89 60 Diclofenac/ Medium Minor "1/'1 (wild-type) 
misoprostol 
3 F 78 45 Diclofenac Medium Minor "1/'3 (heterozygous) 
4 M 62 77 Diclofenac Low Minor *// '1 (wild-type) 
5 M 73 103 Diclofenac Medium Minor *// '1 (wild-type) 
6 F 48 78 Diclofenac Low Minor * / / ' I  (wild-type) 
7 M 76 60 Diclofenac Medium Minor *//*2 (heterozygous) 
8 M 64 77 Diclofenac High Minor *//*2 (heterozygous) 
9 M 70 75 Diclofenac High Minor *//*3 (heterozygous) 
10 F 86 56 Diclofenac Low Minor "1/' I  (wild-type) 
11 M 32 103 Diclofenac Low Minor *//*2 (heterozygous) 
12 M 63 100 Diclofenac Medium Minor *// '1 (wild-type) 
13 F 75 69 Diclofenac Low Minor *// '1 (wild-type) 
14 F 59 58 Ibuprofen Low Major * / / ' I  (wild-type) 
15 M 50 53 Ibuprofen Low Major *//*2 (heterozygous) 
16 F 93 55 I buprofen High Major *// '1 (wild-type) 
17 F 36 63 I buprofen Low Major * / / '1  (wild-type) 
18 F 89 89 Meloxicam Medium Major * / / ' I  (wild-type) 
19 F 80 101 Naproxen High Minor *// '1 (wild-type) 
20 M 68 106 Naproxen High Minor *// '1 (wild-type) 
21 F 82 59 Naproxen High Minor *//*2 (heterozygous) 
22 F 60 56 Naproxen Low Minor * / / ' I  (wild-type) 
23 M 74 95 Rofecoxib High Minor *// '1 (wild-type) 
24 F 89 61 Rofecoxib Low Minor *// '1 (wild-type) 
25 F 82 60 Rofecoxib Medium Minor *//*2 (heterozygous) 
26 F 96 60 Rofecoxib Medium Minor "1/'2 (heterozygous) 
CYP = cytochrome P450; M = male; F = female. 
*Medium = recommended maximum daily dose; low = less than the recommended maximum daily dose; high = more than the 
recommended maximum daily dose. 
tDerived from Scordo et al. 21 
A cohort of 87 consecutive subjects using oral anti- 
coagulants also was sele~ed for CYP2C9 allele analy- 
sis. All subjects were white, 24 (28%) were female, and 
the median age was 69 years (range, 48-81 years). 
The CYP2C9 genotype frequencies for the subjects 
with serious NSAID-related ulcers, the subjects using 
oral coumarin anticoagulants, and subjects in previ- 
ous studies are shown in Table II. CYP2C9 genotype 
frequencies did not differ significandy between the 
subjects with serious NSAID-related ulcers and the 
subjects using oral anticoagulants. The genotype fre- 
quencies in both groups were similar to those in white 
subjects in previous tudies. 17 
In subjects with serious NSAID-related ulcers, the 
genotype frequencies were 65% for CYP2C9'~1/'~1 
(Arg144-Ile359, wild-type), 27% for CYP2C9'~1/'~2 
(Cys144-Ile359) , and 8% for CYP2C9'~1/'~3 (Arg144- 
Leuasg). The homozygous CYP2C9'~2/'2 genotype 
and the homozygous CYP2C9'~3/'~3 genotype were 
not found in the subjects with serious NSAID-related 
i . . . . . . . . .  
Table II. CYP2C9 polymorphisms in white subjects with serious NSAID-related ulcers and subjects using oral 
coumarin anticoagulants (no. [%] of subjects), and in the historical subjects (no.). 
Allele Variant 
Subjects with Serious 
NSAID-Related Ulcers 




(n = 87) 
Historical Cohort 17 




CYP2C9"1/ "3 (heterozygous) 
CYP2C9"2/'3 (compound) 
CYP2C9"3/'3 (homozygous) 
17 (65) 56 (64) 65 
7 (27) 12 (14) 20 
0 0 1 
2 (8) 14 (16) 12 
0 $ (6) 1 
0 0 0 
CYP - cytochrome P450.  
ulcers or in subjects receiving oral anticoagulants. The 
compound heterozygous CYP2C9'~2/'3 genotype was 
not found in subjects with serious NSAID-related ul- 
cers, but it occured at a frequency of 6% in subjects 
using oral anticoagulants (Table II). 
DISCUSSION 
The results of this study suggest hat in these white 
subjects living in The Netherlands, allele variants of 
the CYP2C9 genotype were not a clinically relevant 
risk factor for serious NSAID-related gastroduodenal 
ulcers. 
One possible weakness of this study is that we com- 
pared consecutive subjects from 2 different cohorts, 
the first consisting of subjects with serious NSAID- 
related gastroduodenal ulcers and the second consist- 
ing of subjects using oral anticoagulants. Since it is 
possible that the 2 groups may not have been compa- 
rable in terms of the risk for bleeding, we compared 
the genotype frequencies in these subjects with fre- 
quencies reported in previous tudies./7 
Neither the homozygous CYP2C9'~2/'~2 genotype, 
the homozygous CYP2C9"~3/'~3 genotype, nor the 
compound heterozygous CYP2C9"2/'3 genotype 
was found in the subjects with serious NSAID-related 
ulcers. Twice as many subjects with a heterozygous 
CYP2C9'~1/'~3 genotype were found among the sub- 
jects using oral anticoagulants a  in the subjects with 
serious NSAID-related ulcers. This suggests that, at 
the population level, the CYP2C9 genotype is not 
likely to be a clinically relevant risk factor for the de- 
velopment of serious NSAID-related ulcers. 
Another possible weakness of this study is that 
some of the subjects used more than the maximum 
recommended daily doses of NSAIDs, and others used 
less than the maximum recommended doses. Also, the 
CYP2C9 genotype plays only a small role in the over- 
all clearance of some of the NSAIDs used by the sub- 
jects. 2s Because the serious adverse ffects associated 
with NSAID therapy, such as bleeding and perforated 
gastroduodenal ulcers, are dose related, it is possible 
that the lack of association with CYP2C9 genotypes 
in this study is related to the types and doses of 
NSAIDs used by the subjects. 
The subjects with serious NSAID-related ulcers in 
this study were representative of the subjects een in 
clinical practice; thus, at the population level, the 
CYP2C9 genotype is not likely to be a clinically rele- 
vant risk factor. In an individual subject who is a poor 
metabolizer, however, high doses of NSAIDs whose 
clearance is influenced by CYP2C9 may increase the 
risk for serious NSAID-related ulcers. Future case- 
control studies may answer this question by deter- 
mining CYP2C9 allele frequencies in subjects with 
and without bleeding astroduodenal ulcers who use 
NSAIDs. 
Previous tudies have examined the role of geno- 
type frequencies inthe development of NSAID-related 
ulcers. In one case-control study in 23 white subjects 
with previous NSAID gastropathy and 32 asymptom- 
atic control subjects who used NSAIDs, no significant 
difference in CYP2C9 allele frequencies was found, z~ 
In a larger Spanish case-control study in 94 subjects 
with NSAID-attributable gastrointestinal bleeding and 
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124 asymptomatic control subjects who used NSAIDs, 
the subjects with serious NSAID-related ulcers were 
siguificantly more likely to be carriers of the variant 
CYP2C9"2 allele (P < 0.01) but not of the low- 
metabolizing CYP2C9'~3 allele. 27 
Although CYP2C9 polymorphisms do not appear 
to play a significant role in the development of 
NSAID-related ulcers, their effect may be different in 
subjects who use other drugs concomitantly. Several 
drugs are known to or can be expected to further 
increase the risk for NSAID-related ulcers. These 
include drugs that pharmacodynamically influence 
blood coagulation, such as platelet inhibitors, low- 
dose aspirin, clopidogrel, and dipyridamole, and 
drugs whose pharmacokinetics are influenced by the 
CYP2C9 isozyme ither competitively, as in the case 
of selective serotonin reuptake inhibitors and coumarin 
anticoagulants, or by inhibition of the CYP2C9 iso- 
zyme, as in the case of benzbromarone and amio- 
darone. Also, the mechanism by which some drugs, 
such as corticosteroids, increase the risk for NSAID- 
related ulcers is not completely understood. Subjects 
who are prescribed combined therapy with NSAIDs 
and coumarin anticoagulants are at increased risk of 
bleeding. 2sThe CYP2C9 isozyme catalyzes the metab- 
olism of NSAIDs and coumarin anticoagulants, and 
poor metabolizers who are prescribed this combina- 
tion may be at particular isk for bleeding. Several 
studies have found an association between CYP2C9 
genotypes and coumarin dose requirements29,3°; how- 
ever, studies of the effect of CYP2C9 polymorphisms 
on the NSAID--coumarin interaction have had con- 
flicting results.31, 32 This conflict may be explained by 
the difference in study designs (prospective vs retro- 
spective) and the numbers of subjects included in the 
trials. In our study, only 5 subjects used an NSAID 
and cournarin concomitantly. Four of these subjects 
had the CYP2C9'~1/'1 variant genotype and 1 subject 
had the CYP2C9"1/'2 variant. Future case--control 
studies may resolve this conflict by comparing 
CYP2C9 allele frequencies in subjects with bleeding 
NSAID-related gastroduodenal ulcers who are using 
NSAIDs and coumarin derivatives concomitantly and 
those in subjects using both drugs without bleeding 
complications. 
CONCLUSION 
In this group of white subjects from The Netherlands, 
allele variants of the CYP2C9 genotype were not a 
significant or clinically relevant risk factor for serious 
NSAID-related gastroduodenal ulcers. 
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